Research Analysts Offer Predictions for CAPR FY2025 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a note issued to investors on Wednesday, May 14th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of $1.71 for the year, up from their prior forecast of ($1.11). Cantor Fitzgerald has a “Overweight” rating and a $30.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same period in the previous year, the business posted ($0.31) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $36.40.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $9.44 on Friday. The company has a market capitalization of $431.19 million, a price-to-earnings ratio of -8.91 and a beta of 0.85. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The company’s fifty day moving average price is $10.70 and its two-hundred day moving average price is $13.72.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CAPR. Summit Investment Advisors Inc. lifted its holdings in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 1,345 shares during the last quarter. Krilogy Financial LLC lifted its holdings in shares of Capricor Therapeutics by 9.6% in the 1st quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Capricor Therapeutics by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after buying an additional 2,314 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after buying an additional 2,361 shares during the period. Finally, Invesco Ltd. lifted its stake in Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 2,500 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.